Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
30.6M
-
Number of holders
-
42
-
Total 13F shares, excl. options
-
13M
-
Shares change
-
-1.57M
-
Total reported value, excl. options
-
$45.4M
-
Value change
-
-$5.79M
-
Put/Call ratio
-
0.33
-
Number of buys
-
14
-
Number of sells
-
-21
-
Price
-
$3.48
Significant Holders of Vistagen Therapeutics, Inc. - Common Stock (VTGN) as of Q2 2024
52 filings reported holding VTGN - Vistagen Therapeutics, Inc. - Common Stock as of Q2 2024.
Vistagen Therapeutics, Inc. - Common Stock (VTGN) has 42 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 13M shares
of 30.6M outstanding shares and own 42.59% of the company stock.
Largest 10 shareholders include BVF INC/IL (2M shares), VANGUARD GROUP INC (1.79M shares), COMMODORE CAPITAL LP (1.58M shares), GREAT POINT PARTNERS LLC (1.53M shares), Nantahala Capital Management, LLC (1.52M shares), STEMPOINT CAPITAL LP (1.23M shares), SPHERA FUNDS MANAGEMENT LTD. (809K shares), CITADEL ADVISORS LLC (630K shares), BlackRock Inc. (403K shares), and ARMISTICE CAPITAL, LLC (300K shares).
This table shows the top 42 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.